Skip to main content
Journal cover image

Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.

Publication ,  Journal Article
Strati, P; Fowler, N; Pina-Oviedo, S; Medeiros, LJ; Overman, MJ; Romaguera, JE; Nastoupil, L; Wang, M; Hagemeister, FB; Rodriguez, A; Oki, Y ...
Published in: Clin Lymphoma Myeloma Leuk
January 2018

BACKGROUND: The optimal management of patients with follicular lymphoma Grade 3 (FLG3) is controversial. PATIENTS AND METHODS: This is a case series of 45 patients with FLG3 treated with first-line R-CHOP (rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone) and observed for an extended time interval. RESULTS: The overall response rate was 100% and the median progression-free survival (PFS) has not been reached, with a 3-year PFS of 70%; 14 (31%) patients relapsed, nearly all within 3 years. The baseline characteristic more strongly associated with a shorter PFS were lymph >4 node sites and presence of B symptoms. Three patients later progressed to diffuse large B cell lymphoma, all had baseline elevated serum lactate dehydrogenase level and high International Prognostic Index score. Median overall survival has not been reached. All 4 patients who later developed acute myeloid leukemia were older than 60 years at the time of start of therapy. CONCLUSION: R-CHOP is an effective first-line treatment for patients with FLG3, and might provide extended PFS, comparable with outcomes observed in diffuse large B-cell lymphoma, particularly in subgroups with limited nodal disease.

Duke Scholars

Altmetric Attention Stats
Dimensions Citation Stats

Published In

Clin Lymphoma Myeloma Leuk

DOI

EISSN

2152-2669

Publication Date

January 2018

Volume

18

Issue

1

Start / End Page

e103 / e108

Location

United States

Related Subject Headings

  • Survival Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma, Follicular
  • Humans
  • Female
  • Antineoplastic Combined Chemotherapy Protocols
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Strati, P., Fowler, N., Pina-Oviedo, S., Medeiros, L. J., Overman, M. J., Romaguera, J. E., … Fayad, L. (2018). Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk, 18(1), e103–e108. https://doi.org/10.1016/j.clml.2017.11.001
Strati, Paolo, Nathan Fowler, Sergio Pina-Oviedo, L Jeffrey Medeiros, Michael J. Overman, Jorge E. Romaguera, Loretta Nastoupil, et al. “Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.Clin Lymphoma Myeloma Leuk 18, no. 1 (January 2018): e103–8. https://doi.org/10.1016/j.clml.2017.11.001.
Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, et al. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e103–8.
Strati, Paolo, et al. “Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP.Clin Lymphoma Myeloma Leuk, vol. 18, no. 1, Jan. 2018, pp. e103–08. Pubmed, doi:10.1016/j.clml.2017.11.001.
Strati P, Fowler N, Pina-Oviedo S, Medeiros LJ, Overman MJ, Romaguera JE, Nastoupil L, Wang M, Hagemeister FB, Rodriguez A, Oki Y, Westin J, Turturro F, Neelapu SS, Fayad L. Long-Term Remissions of Patients With Follicular Lymphoma Grade 3 Treated With R-CHOP. Clin Lymphoma Myeloma Leuk. 2018 Jan;18(1):e103–e108.
Journal cover image

Published In

Clin Lymphoma Myeloma Leuk

DOI

EISSN

2152-2669

Publication Date

January 2018

Volume

18

Issue

1

Start / End Page

e103 / e108

Location

United States

Related Subject Headings

  • Survival Analysis
  • Prognosis
  • Middle Aged
  • Male
  • Lymphoma, Follicular
  • Humans
  • Female
  • Antineoplastic Combined Chemotherapy Protocols
  • 3211 Oncology and carcinogenesis
  • 3201 Cardiovascular medicine and haematology